Palvella Therapeutics (PVLA) Free Cash Flow (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Free Cash Flow data on file, last reported at -$10.9 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 61.05% year-over-year to -$10.9 million in Q1 2026; TTM through Mar 2026 was -$29.1 million, a 76.53% decrease from a year earlier, with the FY2025 full-year figure at -$25.0 million, down 130.68% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$10.9 million, down from -$4.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for PVLA reached as high as $20.5 million in Q4 2023 and fell as low as -$23.0 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$7.2 million across 5 years, with a median of -$7.8 million in 2022.
• Across the five-year window, Free Cash Flow jumped 246.74% in 2023 and tumbled 514.16% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$13.9 million in 2022, then soared by 246.74% to $20.5 million in 2023, then slumped by 126.36% to -$5.4 million in 2024, then increased by 9.03% to -$4.9 million in 2025, then slumped by 122.18% to -$10.9 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$10.9 million in Q1 2026, -$4.9 million in Q4 2025, and -$7.9 million in Q3 2025.